98%
921
2 minutes
20
Chronic constipation (CC) is one of the most common conditions found in gastrointestinal clinical practice and defined by the presence of fewer than 3 bowel movements per week and/or more than one fourth of bowel movements with Bristol stool form types 1 or 2. CC affects people regardless of race, age, or sex, although it is most common in women and in elderly. It is associated with relevant disease burden, including significant impairment of patients' quality of life. In the absence of alarm features, patients should receive a symptom-based diagnosis. Treatment options include lifestyle and general measures, bulking agents, in particular dietary fiber supplementation. Osmotic laxatives are currently considered the first-line gold-standard pharmacological treatment of CC together with stimulant laxatives which are often used as a rescue therapy. When necessary, prokinetic agents and/or intestinal secretagogues can be used. Biofeedback may be indicated in patients with functional defecation disorders. In this review, we will briefly summarize the current understanding on epidemiology, classification, pathophysiology and clinical evaluation of CC and discuss in depth the pharmacological and not pharmacological management of patients with this disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S2724-5985.22.03335-6 | DOI Listing |
Microbiol Res
September 2025
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China. Electronic address:
Intractable functional constipation (IFC), a severe form of chronic constipation characterized by slow transit and resistance to conventional treatments, posed a significant clinical challenge. Here, we identified Lactococcus formosensis (Lf), a Gram-positive bacterium prevalent in IFC patients, as a novel contributor to intestinal motility impairment. Clinically, IFC patients exhibited increased colonic mucosal colonization of Lf and significant myenteric neuronal loss and pyroptosis, particularly in excitatory choline acetyltransferase (ChAT) neurons, but not inhibitory neuronal nitric oxide synthase (nNOS) neurons.
View Article and Find Full Text PDFEndocrinol Diabetes Metab Case Rep
July 2025
Department of Internal Medicine, Medical City Arlington, Arlington, Texas, USA.
Summary: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is increasingly used for type 2 diabetes and obesity.
View Article and Find Full Text PDFObjectives: This narrative review identifies pitfalls in managing constipation in older adults and provides evidence-based recommendations to avoid them.
Methods: A selective literature search was conducted across electronic databases (PubMed, MEDLINE, Embase, and Cochrane Library) to identify relevant publications on constipation management in older adults. Randomized controlled trials, meta-analyses, systematic reviews, evidence-based clinical practice guidelines, and selected expert consensus statements and narrative reviews were included.
Front Nutr
August 2025
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Aim: Prior studies have linked obesity indicators to constipation/diarrhea, but multi-measure comparisons remain limited. We analyzed these associations in U.S.
View Article and Find Full Text PDFBMC Neurol
September 2025
Addis Ababa University, Addis Ababa, Ethiopia.
Background: Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.
Methods: PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025.